ASH and The Leukemia & Lymphoma Society Announce Collaboration on Acute Myeloid Leukemia
The American Society of Hematology (ASH) and The Leukemia & Lymphoma Society (LLS) are working together to raise awareness and provide education about the need for new treatments for acute myeloid leukemia (AML), one of the deadliest blood cancers that has not seen a change in the standard of care for more than 40 years.
The two organizations will collaborate to make both patients and health-care practitioners aware of the importance and availability of AML clinical trials, a critical step in the development of new treatments.
“Both LLS and ASH are dedicated to advancing the understanding, diagnosis, and treatment of blood cancers, so our missions are truly aligned,” said LLS President and CEO Louis J. DeGennaro, PhD, in a joint press release. “In AML, we face one of the most critical unmet medical needs in cancer and by joining forces we aim to promote greater understanding of and participation in clinical trials to help bring more effective therapies to patients, faster.”
The initiative is focused on analyzing the genomic causes of the disease – really a constellation of many subtypes – and then identifying agents with the potential to bring these diseases under control. Ultimately, the goal is to develop more precise, individualized, and effective treatments for AML patients. ASH President Charles S. Abrams, MD, said in a statement, “AML continues to present one of our greatest challenges, and ASH welcomes this opportunity to work with LLS to encourage greater participation in clinical trials to advance more therapies and potential cures.”
Look for more information about this collaboration with LLS in future issues of ASH Clinical News and in our other ASH publications. Also, check out our patient information tear sheet that focuses on AML.
Interested in Serving on a Guideline Panel on Sickle Cell Disease?
ASH is seeking members with expertise in this disease.
ASH is developing new clinical practice guidelines on the management of acute and chronic complications of sickle cell disease. Robert Liem, MD, of Ann & Robert H. Lurie Children’s Hospital of Chicago, will chair this guideline effort. The guideline development process will take approximately two years, with anticipated publication in spring 2019. There will be five guideline panels: SCD pain, SCD cerebrovascular disease, SCD cardiopulmonary and kidney disease, SCD stem cell transplantation, and SCD transfusion support.
Given the complex nature of SCD, we are seeking individuals with varied backgrounds and areas of expertise. Each guideline panel will include 10 to 15 people. In addition to hematologists, we expect the panels may include pain specialists, primary-care specialists, pediatricians, nurse practitioners, pharmacists, and other professionals. Both ASH members and non-members may apply or be nominated.
The deadline to apply or submit a nomination is August 15, 2016. Please include the nominee’s name, institution, area of expertise, and email address; nominations should be directed to Starr Webb at firstname.lastname@example.org.
Blood Advances Call for Papers
Blood Advances is ASH’s new open-access journal and the first to join the Blood family in 70 years. You are invited to submit a paper for potential inclusion in Blood Advances, which will begin accepting submissions on August 1, 2016.
Authors who submit their papers to the Blood journal can have their papers reviewed simultaneously by Blood Advances’ editors should the paper not fit into Blood’s scope. This cascading feature is at the author’s discretion at the time of submission. There is no additional cost to the author. This feature will guarantee a quicker route to publication if accepted in Blood Advances. The new journal will also accept direct submissions.
In the May issue of ASH Clinical News, we published an article about the founding editor of Blood Advances, Robert Negrin, MD, who shared his vision for this new journal.
The inaugural issue of the journal will be distributed at the 2016 ASH Annual Meeting in San Diego, California.
Go to bloodadvances.org to learn more about the new journal and to submit a paper. A more detailed website will be available in November.
ASH regularly hosts educational webinars that feature presentations by experts in the field, cover current information on how to best diagnose and care for patients, and provide time for speakers and participants to discuss relevant issues during a question-and-answer session.
Visit ashondemand.org Webinars to access them.
Webinars recently added to ASH On Demand include:
- The FDA’s accelerated approval of daratumumab to treat patients with multiple myeloma who have received at least three prior treatments. Daratumumab is the first monoclonal antibody approved for treating multiple myeloma. The speakers included: Mikkael Sekeres, MD, director, Leukemia Program, professor of medicine, Cleveland Clinic, Cleveland, OH; Nicole Gormley, MD, acting clinical team lead, scientific liaison for multiple myeloma, Division of Hematology Products, U.S. Food and Drug Administration, Silver Spring, MD; and Paul G. Richardson, MD, RJ Corman Professor of Medicine, Harvard Medical School, clinical program leader, director of clinical research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.
- The FDA approval of ixazomib in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy. Ixazomib is the first oral proteasome inhibitor and is approved in combination with lenalidomide and dexamethasone (a type of corticosteroid). The speakers included: David Steensma, MD, Dana-Farber Cancer Institute, Division of Hematological Malignancies, Boston, MA; Alexandria Schwarsin, MD, medical officer, U.S. Food and Drug Administration, Silver Spring, MD; and S. Vincent Rajkumar, MD, Edward W. and Betty Knight Scripps Professor of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN.
Look for two upcoming webinar topics to be added to ASH On Demand in late August: ASH/FDA Update on Nivolumab and ASH/FDA Update on Venetoclax.
vision-for-blood-advances/ASH Endorses Guideline on Care Models for Hemophilia Management
Published in Haemophilia on June 27, 2016, the National Hemophilia Foundation–McMaster University Guideline on Care Models for Hemophilia Management was developed to identify evidence-based best practices in hemophilia care delivery, following specific methods and based on the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach.
This guideline was endorsed by ASH on May 27, 2016. Access the newly published guideline from the ASH website at hematology.org/Clinicians/Guidelines-Quality/3127.aspx.
ASH Data-Sharing Initiative Featured at National Cancer Moonshot Summit
In late June, ASH joined Vice President Joe Biden’s National Cancer Moonshot Summit, a day-long conference intended to jumpstart the Administration’s effort to double the pace of cancer research. ASH is helping to encourage cancer researchers to share data, with the goal of establishing a robust infrastructure of shared multiple myeloma data that will inform better understanding and treatment of this cancer and serve as a model for others.
ASH joined oncology experts from professional, clinical, and research organizations at Howard University in Washington, DC, to foster collaborations around the goals of the National Cancer Moonshot, an initiative that proposes to increase the amount and impact of cancer research both nationally and around the globe by compressing 10 years’ worth of work into the next five. The Cancer Moonshot Summit marked the first time that stakeholders representing all types of cancers convened under one national charge. A major crux of this endeavor is the shared data initiative, which promotes pooling genomic and clinical data among researchers to improve our understanding of cancer and our ability to improve patient outcomes.
To support the Moonshot’s prioritization of data sharing, ASH recently invited myeloma experts from the Multiple Myeloma Research Foundation, the Mayo Clinic, the Dana-Farber Cancer Institute, the University of Arkansas Myeloma Institute, and international partners in the United Kingdom, Spain, France, Germany, and the Netherlands to take the first step toward designing a robust data-sharing infrastructure that will enable basic scientists, clinical researchers, and clinicians to more efficiently interpret and integrate genomic information that can be translated into clinical care.
ASH President-Elect Kenneth C. Anderson, MD, of the Dana-Farber Cancer Institute in Boston, represented ASH in the Summit. Dr. Anderson, an expert in the diagnosis and treatment of multiple myeloma, is leading ASH’s multiple myeloma data-sharing effort.
ASH seeks to create a model that can be used by oncologists of every specialty to collaborate and share data to make great progress in defeating cancer.
“ASH is not only creating an infrastructure for sharing data on the treatment, care, and cure for myeloma,” said Dr. Anderson, “we are establishing a model for basic scientists, clinical researchers, and clinicians from around the world to join together and work toward improved patient outcomes with more potent, selective, and well-tolerated therapies.”
Visit hematology.org/Research/Recommendations/Moonshot-Initiative to read about ASH’s recommendations for the Moonshot Initiative.